Intimation of Resignation of Managing Director under regulation 30 of SEBI(LODR) Regulation 2015

CEO resignedCFO resignedKey managerial personnel resignedManagement Changes View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.7%Reaction day

₹0.85

prior close

₹0.85

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.3%+3.4% vs market

Pharmaceuticals peers, median of 146sector+0.5%+4.2% vs sector

On the reaction day the stock moved 3.4 pts more than Nifty Microcap 250 and 4.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.0

15m

+4.7

30m

+4.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.7+1.3+3.4+0.5+4.2

Next day

+9.4+0.4+9.0-0.5+9.9

+15.3+0.3+15.0-0.8+16.1

+18.8+5.0+13.9+2.3+16.5

+20.0+6.7+13.3+2.9+17.1

+22.4+8.4+14.0+3.8+18.6

+25.9+10.3+15.6+4.8+21.0

15d

+27.1+12.8+14.2+7.3+19.8

+22.4+16.0+6.3+5.9+16.4

+24.7+16.9+7.8+8.3+16.4

+12.9+12.5+0.4+5.3+7.7

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 146Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Mr. Altaf Hussain (DIN: 10351528) has resigned from the dual role of Managing Director and Chief Financial Officer of Welcure Drugs & Pharmaceuticals Ltd, effective from close of business hours on 5th May 2025. He cited personal reasons and other professional commitments for his departure, and confirmed there are no other material reasons behind his exit. The Board of Directors has acknowledged his resignation and recorded appreciation for his contributions during his tenure. The resignation was communicated to BSE on 6th May 2025 under Regulation 30 of SEBI (LODR) Regulations, and the company has stated he holds no other directorships in listed entities.

Likely market impact

The sudden exit of the person handling both the MD and CFO roles could create short-term leadership and financial oversight uncertainty. Shareholders should watch for timely disclosures regarding interim arrangements and the appointment of a new MD and/or CFO, as prolonged vacancies at this level may affect investor confidence and stock sentiment.